• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Dow Edges Higher; QuidelOrtho Shares Plummet

    2/14/24 2:32:55 PM ET
    $AZTR
    $ENGN
    $HCSG
    $LYFT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $AZTR alert in real time by email

    U.S. stocks traded mostly higher toward the end of trading, with the Nasdaq Composite gaining around 100 points on Wednesday.

    The Dow traded up 0.11% to 38,313.27 while the NASDAQ rose 0.70% to 15,765.18. The S&P 500 also rose, gaining, 0.49% to 4,977.43.

    Check This Out: Snap, American Express And 2 Other Stocks Insiders Are Selling

     

    Leading and Lagging Sectors

     

    Industrials shares rose by 1.1% on Wednesday.

    In trading on Wednesday, consumer staples shares fell by 0.6%.

     

    Top Headline

     

    Crude oil inventories in the U.S. surged by 12.018 million barrels in the week ending Feb. 9, compared to market estimates of a 2.56 million rise.

     

    Equities Trading UP

     

    enGene Holdings Inc. (NASDAQ:ENGN) shares shot up 83% to $13.95. The company’s CEO Jason Hanson is resigning due to personal family and health reasons, though he will continue to support the company as a strategic advisor after a successor is appointed. Concurrently, enGene announced a private placement of 20 million common shares at $10.00 per share, representing a 31% premium over the previous day’s closing price.

    Shares of Lyft, Inc. (NASDAQ:LYFT) got a boost, surging 33% to $16.10 after the company reported fourth-quarter sales of $1.22 billion and gross bookings of $3.7 billion, up 17% year-over-year. The company’s CFO, Erin Brewer, said the adjusted EBITDA margin is projected to expand 50 basis points in 2024.

    Healthcare Services Group, Inc. (NASDAQ:HCSG) shares were also up, gaining 26% to $11.91 following upbeat earnings.

     

    Equities Trading DOWN

     

    Azitra, Inc. (NYSE:AZTR) shares dropped 71% to $0.2540. Azitra priced its $5 million public offering of 16.667 million common shares at $0.30 per share.

    Shares of QuidelOrtho Corporation (NASDAQ:QDEL) were down 29% to $47.17 after the company reported worse-than-expected fourth-quarter financial results and issued FY24 adjusted EPS below estimates.

    Ohmyhome Limited (NASDAQ:OMH) was down, falling 38% to $1.40 after the company priced its upsized $4.8 million public offering of 3,555,555 ordinary shares at $1.35 per share.

    Also Check This Out: Retractable Technologies And 2 Other Stocks Under $5 Insiders Are Buying

     

    Commodities

     

    In commodity news, oil traded down 1.2% to $76.95 while gold traded down 0.2% at $2,004.20.

    Silver traded up 1.2% to $22.425 on Wednesday while copper fell 0.3% to $3.6985.

     

    Euro zone

     

    European shares closed mostly higher today. The eurozone’s STOXX 600 gained 0.50%, London’s FTSE 100 rose 0.75% while Spain’s IBEX 35 Index fell 0.09% The German DAX rose 0.38% French CAC 40 rose 0.68% while Italy’s FTSE MIB Index rose 0.63%.

    The Eurozone economy stagnated in the final quarter of 2023, compared to a 0.1% decline in the prior three-month period. Industrial production in the Eurozone increased by 2.6% month-over-month in December.

    The UK’s inflation rate came in unchanged at 4.0% in January, compared to market estimates of 4.2%. Factory gate prices of goods produced by UK manufacturers fell 0.6% year-over-year in January following a 0.1% increase in December.

     

    Asia Pacific Markets

     

    Asian markets closed mixed on Wednesday, with Japan’s Nikkei 225 falling 0.69%, Hong Kong’s Hang Seng Index gaining 0.84% and India’s S&P BSE Sensex gaining around 0.5%.

    India’s wholesale prices increased by 0.27% year-over-year in January, compared to 0.73% in December.

     

    Economics

     

    U.S. mortgage applications declined by 2.3% in the week ending Feb. 9, compared to a 3.7% increase in the prior week.

    Crude oil inventories in the U.S. surged by 12.018 million barrels in the week ending Feb. 9, compared to market estimates of a 2.56 million rise.

    Now Read This: Wall Street's Most Accurate Analysts' Views On 3 Health Care Stocks Delivering High-Dividend Yields

    Get the next $AZTR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AZTR
    $ENGN
    $HCSG
    $LYFT

    CompanyDatePrice TargetRatingAnalyst
    enGene Holdings Inc.
    $ENGN
    1/30/2026$28.00Buy
    Jefferies
    Lyft Inc.
    $LYFT
    12/19/2025$16.00Neutral → Underperform
    Wedbush
    Lyft Inc.
    $LYFT
    12/3/2025$20.00Sell → Neutral
    Arete
    Healthcare Services Group Inc.
    $HCSG
    11/13/2025$20.00Market Perform
    BMO Capital Markets
    enGene Holdings Inc.
    $ENGN
    11/11/2025$27.00Outperform → Strong Buy
    Raymond James
    Lyft Inc.
    $LYFT
    10/15/2025$22.00Buy
    Guggenheim
    QuidelOrtho Corporation
    $QDEL
    10/7/2025$33.00Buy → Neutral
    Citigroup
    Lyft Inc.
    $LYFT
    9/30/2025$24.00Neutral
    Mizuho
    More analyst ratings

    $AZTR
    $ENGN
    $HCSG
    $LYFT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    QuidelOrtho Reports Fourth Quarter and Full-Year 2025 Financial Results

    ― Delivered 6% Labs and 9% TRIAGE™ growth, as reported, and 240 bps of adjusted EBITDA margin expansion in FY25 ― ― Continued growth and margin expansion expected in FY26; free cash flow expected to improve by over $200 million ― SAN DIEGO, Feb. 11, 2026 /PRNewswire/ -- QuidelOrtho Corporation (NASDAQ:QDEL) (the "Company" or "QuidelOrtho"), a global leader of innovative in vitro diagnostics, today announced financial results for the fourth quarter and full-year ended December 28, 2025. "In 2025, we transitioned from COVID-driven volatility to a more durable, diversified diagno

    2/11/26 4:05:00 PM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Healthcare Services Group Reports Full Year and Fourth Quarter Results

    Exceeds 2025 Expectations Announces New Share Repurchase Program Provides 2026 Growth Outlook Revenue: $1.84 billion for the year (+7.1%) and $466.7 million for the quarter (+6.6%). Net income and EPS: $59.1 million or $0.81 for the year and $31.2 million or $0.44 for the quarter. Cash flow from operations: $145.0 million for the year and $17.4 million for the quarter. Excluding change in payroll accrual, $164.1 million for the year and $36.4 million for the quarter. Share repurchase: Completes $50.0 million buyback and authorizes new $75.0 million, 12-month program. 2026 outlook: Expects mid-single-digit revenue growth. Healthcare Services Group, Inc. (NASDAQ:HCSG) to

    2/11/26 7:00:00 AM ET
    $HCSG
    Hospital/Nursing Management
    Health Care

    Lyft Reports Record Q4 and Full-Year 2025 Results

    Delivered accelerated Q4 Gross Bookings growth year over year; on track with 2027 targets Announces new $1 billion share repurchase program Lyft, Inc. (NASDAQ:LYFT) today announced record financial results for the fourth quarter and full year ended December 31, 2025. "2025 was an incredible year in Lyft's comeback story. Through customer obsession, we're transforming from your local, "out-to-dinner" rideshare app to a global, hybrid transportation platform," said CEO David Risher. "As we look ahead, we are entering a transformational phase for Lyft - 2026 will be the year of the AV with deployments in the U.S. and overseas." "We delivered record financial performance in 2025 across

    2/10/26 4:05:00 PM ET
    $LYFT
    Real Estate

    $AZTR
    $ENGN
    $HCSG
    $LYFT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Jefferies initiated coverage on enGene Holdings with a new price target

    Jefferies initiated coverage of enGene Holdings with a rating of Buy and set a new price target of $28.00

    1/30/26 6:43:51 AM ET
    $ENGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Lyft downgraded by Wedbush with a new price target

    Wedbush downgraded Lyft from Neutral to Underperform and set a new price target of $16.00

    12/19/25 8:45:08 AM ET
    $LYFT
    Real Estate

    Lyft upgraded by Arete with a new price target

    Arete upgraded Lyft from Sell to Neutral and set a new price target of $20.00

    12/3/25 8:26:11 AM ET
    $LYFT
    Real Estate

    $AZTR
    $ENGN
    $HCSG
    $LYFT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Risher John David bought $99,617 worth of shares (5,030 units at $19.80), increasing direct ownership by 0.04% to 11,802,296 units (SEC Form 4)

    4 - Lyft, Inc. (0001759509) (Issuer)

    12/11/25 8:53:23 PM ET
    $LYFT
    Real Estate

    Director Rhoads Ann D bought $21,206 worth of shares (750 units at $28.27), increasing direct ownership by 5% to 15,021 units (SEC Form 4)

    4 - QuidelOrtho Corp (0001906324) (Issuer)

    12/10/25 6:37:17 PM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Director Wilkins Joseph D Jr. bought $10,343 worth of shares (370 units at $27.95), increasing direct ownership by 3% to 11,876 units (SEC Form 4)

    4 - QuidelOrtho Corp (0001906324) (Issuer)

    12/1/25 4:33:10 PM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $AZTR
    $ENGN
    $HCSG
    $LYFT
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by QuidelOrtho Corporation

    SCHEDULE 13G - QuidelOrtho Corp (0001906324) (Subject)

    2/12/26 3:57:06 PM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    QuidelOrtho Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - QuidelOrtho Corp (0001906324) (Filer)

    2/11/26 4:07:04 PM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Healthcare Services Group Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - HEALTHCARE SERVICES GROUP INC (0000731012) (Filer)

    2/11/26 7:01:50 AM ET
    $HCSG
    Hospital/Nursing Management
    Health Care

    $AZTR
    $ENGN
    $HCSG
    $LYFT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Legal Officer Hodges Michelle A was granted 3,198 shares and covered exercise/tax liability with 1,148 shares, increasing direct ownership by 5% to 41,605 units (SEC Form 4)

    4 - QuidelOrtho Corp (0001906324) (Issuer)

    2/10/26 4:10:25 PM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Chief Financial Officer Busky Joseph M. was granted 5,968 shares and covered exercise/tax liability with 1,806 shares, increasing direct ownership by 11% to 41,412 units (SEC Form 4)

    4 - QuidelOrtho Corp (0001906324) (Issuer)

    2/10/26 4:09:58 PM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form 4 filed by Chief Human Resources Officer Bowman Ronald Lee

    4 - QuidelOrtho Corp (0001906324) (Issuer)

    2/3/26 7:51:39 PM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $AZTR
    $ENGN
    $HCSG
    $LYFT
    Financials

    Live finance-specific insights

    View All

    QuidelOrtho Reports Fourth Quarter and Full-Year 2025 Financial Results

    ― Delivered 6% Labs and 9% TRIAGE™ growth, as reported, and 240 bps of adjusted EBITDA margin expansion in FY25 ― ― Continued growth and margin expansion expected in FY26; free cash flow expected to improve by over $200 million ― SAN DIEGO, Feb. 11, 2026 /PRNewswire/ -- QuidelOrtho Corporation (NASDAQ:QDEL) (the "Company" or "QuidelOrtho"), a global leader of innovative in vitro diagnostics, today announced financial results for the fourth quarter and full-year ended December 28, 2025. "In 2025, we transitioned from COVID-driven volatility to a more durable, diversified diagno

    2/11/26 4:05:00 PM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Healthcare Services Group Reports Full Year and Fourth Quarter Results

    Exceeds 2025 Expectations Announces New Share Repurchase Program Provides 2026 Growth Outlook Revenue: $1.84 billion for the year (+7.1%) and $466.7 million for the quarter (+6.6%). Net income and EPS: $59.1 million or $0.81 for the year and $31.2 million or $0.44 for the quarter. Cash flow from operations: $145.0 million for the year and $17.4 million for the quarter. Excluding change in payroll accrual, $164.1 million for the year and $36.4 million for the quarter. Share repurchase: Completes $50.0 million buyback and authorizes new $75.0 million, 12-month program. 2026 outlook: Expects mid-single-digit revenue growth. Healthcare Services Group, Inc. (NASDAQ:HCSG) to

    2/11/26 7:00:00 AM ET
    $HCSG
    Hospital/Nursing Management
    Health Care

    QuidelOrtho to Report Fourth Quarter and Full-Year 2025 Financial Results

    SAN DIEGO, Jan. 21, 2026 /PRNewswire/ -- QuidelOrtho Corporation (NASDAQ:QDEL) (the "Company" or "QuidelOrtho"), a global leader of in vitro diagnostics, announced today that it will report its financial results for the fourth quarter and full year 2025 ended December 28, 2025, after the market close on Wednesday, February 11, 2026. Following the release of financial results, QuidelOrtho will hold a conference call beginning at 2:00 p.m. PT / 5:00 p.m. ET to discuss its financial results. Interested parties can access the call from the "Events & Presentations" section of the "

    1/21/26 7:00:00 AM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $AZTR
    $ENGN
    $HCSG
    $LYFT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by QuidelOrtho Corporation

    SC 13G/A - QuidelOrtho Corp (0001906324) (Subject)

    12/6/24 10:11:24 AM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Amendment: SEC Form SC 13G/A filed by Lyft Inc.

    SC 13G/A - Lyft, Inc. (0001759509) (Subject)

    12/4/24 2:38:58 PM ET
    $LYFT
    Real Estate

    Amendment: SEC Form SC 13D/A filed by QuidelOrtho Corporation

    SC 13D/A - QuidelOrtho Corp (0001906324) (Subject)

    11/21/24 5:10:19 PM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $AZTR
    $ENGN
    $HCSG
    $LYFT
    Leadership Updates

    Live Leadership Updates

    View All

    enGene Appoints Hussein Sweiti, M.D., MSc, as Chief Medical Officer

    Bladder cancer development leader who helped drive recent FDA product approval in NMIBC joins to lead research and development strategy Appointment strengthens enGene's clinical development and regulatory capabilities ahead of planned 2H 2026 BLA submission for detalimogene enGene Holdings Inc. (NASDAQ:ENGN, "enGene" or the "Company")), a clinical-stage, non-viral genetic medicine company, today announced that Hussein Sweiti, M.D., MSc, was appointed Chief Medical Officer, effective September 29, 2025. Dr. Sweiti is a surgical oncologist and physician-scientist with more than 15 years of experience spanning clinical practice, oncology clinical research, global drug development, regula

    9/30/25 7:30:00 AM ET
    $ENGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    QuidelOrtho Welcomes Erich Wolff as Executive Vice President, Strategy & Corporate Development

    SAN DIEGO, Aug. 19, 2025 /PRNewswire/ -- QuidelOrtho Corporation (NASDAQ:QDEL) (the "Company" or "QuidelOrtho"), a global leader of in vitro diagnostics, welcomes Erich Wolff as Executive Vice President, Strategy & Corporate Development. In this role, Mr. Wolff will report directly to President and Chief Executive Officer Brian Blaser, and he will lead the Company's enterprise strategy, business development, government affairs and portfolio management functions. Mr. Wolff brings over two decades of leadership experience in strategy, M&A and business development across the heal

    8/19/25 4:05:00 PM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    enGene Announces Board and Leadership Appointments to Support Commercial Readiness

    Philip Astley-Sparke, William Grossman and Michael Heffernan join the Board Management promotions strengthen clinical and regulatory operations Matthew Boyd named Chief Regulatory Officer, Jill Buck Chief Development Officer, and Katherine Chan Executive Director, Urology Clinical Lead enGene Holdings Inc. (NASDAQ:ENGN), a clinical-stage, non-viral gene-based immunotherapy company, today announced the appointment of three new members to its Board of Directors: Philip Astley-Sparke, William Grossman, M.D., Ph.D., and Michael Heffernan, R.Ph. Their combined experience across gene therapy, oncology, clinical development, and global product launches will support enGene's strategic transit

    7/8/25 8:00:00 AM ET
    $ENGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care